NS Pharma, Inc.
Angela Melia, PMP has extensive experience in clinical research and operations, holding various leadership positions at NS Pharma, Inc., Chugai Pharma USA, Inc., and Hoffmann-La Roche, Inc. Angela is accountable for planning, coordination, and performance management of clinical trials in orphan rare diseases. Angela has also been recognized for excellence in sponsor-site relationship management. Angela holds a Mini-MBA in BioPharma Innovation Certificate Program from Rutgers University and a B.S. in Biology/Pre-med magna cum laude from Seton Hall University.
This person is not in any offices
NS Pharma, Inc.
2 followers
NS Pharma, Inc. (NSP) located in Paramus New Jersey is a subsidiary of Nippon Shinyaku Co., Ltd. Founded in 1999 in the United States, NSP is engaged in clinical studies and partnering with global pharmaceutical companies, venture companies and research institutes. NSP serves as a contact point for connecting Japan/Asia and the world, developing drug candidates invented in Japan and out-license them to the world. From the world to Japan/Asia, NSP in-license promising drug candidates to the Japanese/Asian Markets. In coordination with parent company, Nippon Shinyaku, Co., Ltd., NSP will first and foremost develop and supply safe and highly effective pharmaceuticals through clinical studies. NSP aims to be an indispensable entity in the healthcare industry in line with the guidelines for action “Challenge”, “Speed”, and “Investigation”.